Glycomacropeptide formula with docosahexaenoic acid and low phenylalanine

PBAC's latest decision on Glycomacropeptide formula with docosahexaenoic acid and low phenylalanine: Recommended (2019). Considered for Dietary management of phenylketonuria (PKU).

Eligible population

Patients with phenylketonuria (PKU) requiring dietary management via oral liquid glycomacropeptide formula.

Therapy area

Metabolic

Line of therapy

Not applicable

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

PKU Glytactin RTD 10

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Similar precedents

• Glycomacropeptide formula with docosahexaenoic acid with low phenylalanine
  similarity 0.96
• Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine
  similarity 0.89
• Glycomacropeptide formula with amino acids, vitamins, minerals, trace elements, carbohydrate, fat and low phenylalanine
  similarity 0.88
• Glycomacropeptide formula with amino acids and low phenylalanine
  similarity 0.87
• Glycomacropeptide and essential amino acids with vitamins and minerals
  similarity 0.84
• Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low phenylalanine
  similarity 0.85